Mycoses in Pediatric Patients

William J. Steinbach, Thomas J. Walsh

Research output: Contribution to journalReview article

Abstract

For more than 40 years, there has been limited progress in the treatment of invasive fungal infections. There are now numerous nuances to choosing the appropriate antifungal agent. Important advances have been achieved in understanding the safety, tolerability, and pharmacokinetics of these agents. One of the most important aspects for successful management of pediatric invasive fungal infections is an understanding of the differences in the pharmacokinetics of the drug in children and adults to offer optimal dosing strategies. Unfortunately there have been few antifungal studies conducted in children. Consequently most information for the pediatrician has been extrapolated from adult data. The breadth of antifungal data in children is expanding, however, with newer studies underway. Through the efforts of dedicated clinicians and collaboration, pediatric indications and dosing strategies will eventually be discovered that directly benefit pediatric patients.

Original languageEnglish (US)
Pages (from-to)663-678
Number of pages16
JournalInfectious disease clinics of North America
Volume20
Issue number3
DOIs
StatePublished - Sep 1 2006

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Mycoses in Pediatric Patients'. Together they form a unique fingerprint.

  • Cite this